Body Composition–Based Nutritional Status During Neoadjuvant Chemotherapy and Its Association with Relative Dose Intensity and Hematologic Toxicity in Patients with Gastric Cancer

Why It Matters

Preserving muscle and water stores during neoadjuvant therapy can help maintain chemotherapy intensity, which is critical for improving survival outcomes in gastric cancer patients.

Key Takeaways

• Muscle loss during neoadjuvant therapy predicts lower chemotherapy dose intensity
• Higher skeletal muscle mass reduces risk of grade 2 thrombocytopenia
• Total body water loss correlates with reduced relative dose intensity
• Body fat mass shows no significant impact on chemotherapy dose delivery
• Bioelectrical impedance analysis offers a practical way to monitor patients

Pulse Analysis

Neoadjuvant chemotherapy is a cornerstone of curative treatment for locally advanced gastric cancer, yet its success hinges on delivering the planned drug dose. Relative dose intensity (RDI) serves as a proxy for treatment fidelity, and reductions below 85 % have been repeatedly linked to inferior survival. Traditional dosing calculations rely on body surface area, ignoring the nuanced role of lean tissue, fat, and hydration status in drug pharmacokinetics. Recent research highlights that patients who maintain or gain muscle and total body water during therapy are more likely to achieve full‑dose delivery, underscoring the need to look beyond weight alone when planning regimens.

The Frontiers in Nutrition investigation employed a multi‑frequency bioelectrical impedance analysis (BIA) device to capture five key composition metrics—muscle mass, skeletal muscle mass, body‑fat mass, visceral fat area, and total body water—both before and after neoadjuvant treatment. Multivariate models revealed that each standard‑deviation increase in muscle or water content cut the odds of reduced RDI by roughly 20‑30 %, while fat‑related measures had no meaningful association. Moreover, only grade 2 thrombocytopenia showed a clear link to composition changes, with higher skeletal muscle mass offering a protective effect. These findings suggest that lean tissue reserves act as a physiological buffer against chemotherapy‑induced hematologic stress.

Clinically, the study advocates for routine BIA monitoring as a low‑cost, radiation‑free tool to identify patients at risk of dose attenuation. Interventions such as targeted nutrition, resistance training, or early physiotherapy could be deployed to preserve muscle and hydration, potentially averting dose reductions and improving outcomes. Future trials should test whether proactive body‑composition optimization translates into higher RDI, reduced toxicities, and ultimately better long‑term survival, moving gastric‑cancer care toward a more personalized, composition‑aware paradigm.